Paul Herzich was Appointed as Chief Technology Officer at AavantiBio

Date of management change: April 13, 2021 

What Happened?

Cambridge, MA-based AavantiBio Appointed Paul Herzich as Chief Technology Officer

 

About the Company

AavantiBio is a pre-clinical biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high for which there are typically no approved therapies treating the underlying disease. AavantiBio is headquartered in Cambridge, MA with additional locations in Gainesville, FL. We are looking for exceptional individuals who share our passion for developing novel therapies to treat rare diseases and advancing the field of gene transfer therapy. Developing genetic treatments for rare diseases is inspiring but challenging work and it takes dedication and courage which will make a meaningful impact on those who suffer from rare diseases. At AavantiBio, we will push each other to perform at our very best, and build a company that not only our employees are proud of, but also the rare disease community, because everyone knows we are trying to make a difference in patients` lives. Come join our team!

 

About the Person

Paul Herzich is Chief Technology Officer at AavantiBio. Previously, Paul held various senior IT leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Stein Sebastian, Piper Sean, Heasman John, Dushatsky Feliks, O'Reilly Mark, Jatczak Kenneth, Burnett Chris, Reynolds Ryan, Von Vreckin Kevin, Weinman Angela, Siudara Andrea

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.